Recently, it has been reported that the orphan nuclear receptor estrogen-related receptor α (ERRα) is involved in the osteogenic differentiation of mesenchymal stem cells (MSCs). Moreover, ERRα has been identified as a novel therapeutic target for treating osteoporosis and other bone diseases. Human periodontal ligament tissue-derived mesenchymal stem cells (hPDLSCs) have recently been used in stem cell-mediated therapies because of their multipotency, particularly toward osteogenic differentiation. However, it is still unclear whether ERRα can regulate the osteogenic differentiation of hPDLSCs. In the present study, we investigated the role of ERRα in the osteogenic differentiation of hPDLSCs in vitro. We isolated hPDLSCs and confirmed their capacity for multipotent differentiation. Furthermore, we examined ERRα expression in hPDLSCs by RT-PCR and immunocytochemistry. We found that the expression of ERRα mRNA was significantly increased during the late stage of osteogenic differentiation of hPDLSCs. Moreover, transfection of recombinant lentiviral-mediated miRNA targeting ERRα significantly suppressed ALP activity, mineralization capacity, and the mRNA expression of osteogenesis-related genes (ALP, OCN, RUNX2 and OPN) in hPDLSCs. Our results indicate that ERRα may promote the osteogenic differentiation of hPDLSCs in vitro.
Introduction
Estrogen-related receptor α (ERRα, NR3B1) is among the first orphan nuclear receptors identified by low-stringency screening of cDNA libraries with a probe encompassing the DNA binding domain of human estrogen receptor (ER) α (1) . ERRα shares only 37% amino acid identity in its ligand binding domain with ERα (1) , which may explain the fact that ERRα does not bind estrogen. Instead, ERRα activates gene transcription constitutively in a ligand-independent manner (2) . ERRα is involved in various physiological regulatory processes. It is a regulator of energy metabolism (3, 4) , and is essential for adaptive thermogenesis (5) . ERRα is also related to the growth and progression of several gynecological cancers (6, 7) . ERRα is regulated by estrogen in bone, and it may play a functional role in diseases caused by estrogen deficiency, such as osteoporosis (8) . ERRα is expressed throughout osteoblastic differentiation and may regulate bone formation both in vitro (9) and in vivo (10) , and it is also involved in osteoclast adhesion and transmigration (11) . Since osteoblasts arise from multipotent mesenchymal stem cells (MSCs), several studies have investigated the role of ERRα in the osteogenic differentiation of MSCs. Various studies have designated ERRα as an activator of osteogenic differentiation of MSCs (12, 13) , whereas other studies have suggested that ERRα is an inhibitor (14, 15) . Therefore, the function of ERRα in osteogenic differentiation of MSCs has not been clearly understood.
Human periodontal ligament tissue-derived mesenchymal stem cells (hPDLSCs), first isolated by Seo et al (16) in 2004, are multipotent stem cells that have been recently used in stem cell-mediated therapies and tissue engineering (17, 18) . Studies have shown that hPDLSCs have an osteogenic potential both in vitro and in vivo, but the molecular mechanisms that underlie hPDLSC differentiation toward an osteoblastic phenotype remain elusive (19) .
Thus, we hypothesized that ERRα may be expressed in PDLSCs and may be involved in the osteogenic characteristic of PDLSCs. In the present study, we found that ERRα was expressed in hPDLSCs. Moreover, the expression level of ERRα was increased during the late period of osteogenic differentiation of hPDLSC. To confirm the role of ERRα in osteogenic differentiation of hPDLSCs, we used lentiviral delivery of miRNA to knock down the expression of ERRα in hPDLSCs, and found that the osteogenic potential of hPDLSCs was impaired after ERRα silencing. Our data indicate that ERRα may play an important role in osteogenic differentiation of hPDLSCs and may be used to improve the osteogenic potential of hPDLSCs. Thus, hPDLSCs may be a promising therapeutic target for the treatment of some bone diseases.
Materials and methods
Cell culture. Periodontal ligament (PDL) tissues were harvested from healthy premolars extracted for orthodontic reasons. Seven donors (12-16 years of age; four females and three males) and their parents provided informed consent. Approval was granted by the Ethics Committee of the School of Stomatology at the Fourth Military Medical University, China. PDL tissue attached to the middle third of the root was removed and cultured in phenol red-free α-MEM supplemented with 10% charcoal-treated FBS (both from Gibco-BRL, Rockville, MD, USA), 2 mmol/l glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin at 37˚C in a humidified atmosphere with 5% CO 2 . After reaching 100% confluence, the cells were subcultured. To obtain homogeneous populations of PDLSCs, the limiting dilution technique was used as described previously (20) . After 2-3 weeks in culture, single cell-derived clones were harvested and combined. Multiple colony-derived PDLSCs at passage 3 or 4 were used in experiments. The human breast adenocarcinoma cell line MCF-7 was cultured in the same manner and served as a positive control.
Flow cytometric analysis. The isolated putative hPDLSCs were collected and washed with PBS. To identify the PDLSC phenotype, ~3x10 6 hPDLSCs were incubated with Alexa Fluor-conjugated monoclonal antibodies against human STRO-1 (340104), CD29 (303016), CD34 (343518), CD45 (304019) and CD105 (323209) (all from BioLegend, San Diego, CA, USA) for 2 h on ice. After washing twice and resuspending in PBS, the cells were analyzed using an Epics XL (Beckman Coulter, Fullerton, CA, USA).
Adipogenic induction. Adipogenic induction medium consisted of α-MEM supplemented with 10% FBS, 2 µmol/l insulin (I6279), 0.5 mmol/l isobutyl-methylxanthine (I5879) and 10 nmol/l dexamethasone (D1756) (all from Sigma-Aldrich, St. Louis, MO, USA). PDLSCs were incubated in adipogenic induction medium for 14 days. The medium was replaced every other day. Intracellular lipid accumulation was detected by staining with Oil Red O (O0625; Sigma-Aldrich).
Osteogenic induction. Osteogenic induction medium consisted of α-MEM supplemented with 10% FBS, 10 mmol/l β-glycerophosphate (G6251), 10 nmol/l dexamethasone, and 50 µg/ml ascorbic acid (A5960) (both from Sigma-Aldrich). PDLSCs were incubated in osteogenic induction medium for 21 days. The medium was replaced every other day. For ALP staining, cells were fixed and stained using a BCIP/NBT Alkaline Phosphatase Color Development Kit (Beyotime, Haimen, China). Calcium accumulation was detected by staining with 2% Alizarin Red S (pH 8.3, A5533; SigmaAldrich), and then rinsing extensively with PBS. After images of the nodules were recorded, 10% (w/v) cetylpyridinium chloride (Sigma-Aldrich) was used to dissolve the nodules, and the absorbance was examined at 562 nm.
RNA extraction and RT-PCR. Total RNA from PDLSCs was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. cDNA was synthesized from mRNA using M-MLV reverse transcriptase (Invitrogen). Primer sequences for ERRα and β-actin are shown in Table I . After predenaturation at 94˚C for 5 min, 30 PCR cycles were performed (94˚C for 30 sec; 57˚C for 30 sec; and 72˚C for 30 sec), followed by a final extension at 72˚C for 10 min. PCR products were separated on 1.5% agarose gels containing ethidium bromide by electrophoresis and then visualized by a UV transilluminator.
Immunocytochemical analysis. PDLSCs and MCF-7 cells (positive control) were seeded on coverslips at a density of 5x10 3 cells/ml for 48 h, and then fixed with cold acetone. Immunocytochemical analysis was performed using the streptavidin-biotin complex method according to the manufacturer's protocol (Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China). DAB was used as the chromogen. The primary antibody against ERRα was a monoclonal rabbit anti-human ERRα (ab41868; Abcam, Cambridge, UK) at a 1:100 dilution. For the negative control, the primary antibody was substituted with a commensurable volume of PBS. The samples were counterstained with hematoxylin and examined under an Olympus compound microscope (Olympus, Tokyo, Japan) equipped with a Nikon digital camera (Nikon, Tokyo, Japan).
Viral vector construction and transduction. The BLOCK-iT™
RNAi Designer Program (Invitrogen) was used to design the miRNA sequence targeting the human ERRα gene. The target sequence was GCTACCCTCTGTGACCTCTTT. The annealed DNA sequences were cloned into pcDNA6.2-GW/EmGFP-miR (Invitrogen). The lentiviral vector plasmids were derived from the pLenti6.3/V5-Dest construct using the BLOCK-iT Lentiviral Pol II miR RNAi Expression System with EmGFP (Invitrogen), according to the manufacturer's instructions. Briefly, pcDNA6.2-GW/EmGFP-ERRα-miR was recombined into the pLenti6.3/V5-Dest vector. The reaction mixtures were transformed into DH5α competent cells to select for positive clones. Sequencing was performed to verify the recombinant pLenti-ERRα-miR plasmid. Lentiviruses were produced by transient transfection of 293FT cells using Lipofectamine 2000, lentiviral vectors, and packaging mix (Invitrogen). Transfection of hPDLSCs was performed by exposure to viral supernatant at a MOI of 100 in the presence of Polybrene (8 mg/ml; Sigma-Aldrich) for 48 h. To produce stably transfected cell lines, the cells were cultured in selection medium containing 5 µg/ml blasticidin (Invitrogen) for 2 weeks. The cells were cultured in α-MEM supplemented with 10% FBS and 2.5 µg/ml blasticidin to maintain and expand the cells.
Quantitative real-time PCR analysis. PDLSCs were treated with osteogenic induction medium, or cultured in standard medium as the control group. The cells were harvested at day 1, 5, 10, 15 and 20. Lentivirus-transduced PDLSCs were harvested after infection for 48 h to determine the efficiency of ERRα gene knockdown. After the production of stably transfected cell lines, osteogenic induction was performed, and the cells were harvested at day 7, 14 and 21. Total RNA isolation and first-strand cDNA synthesis were performed as described above. Real-time PCR was carried out with a Mastercycler ep Realplex4 (Eppendorf AG, Hamburg, Germany) and SYBR-Green (Invitrogen). Primer sequences are shown in Table I . Reactions were performed under the following cycling conditions: 95˚C for 10 min, followed by 45 cycles of 95˚C for 15 sec and 60˚C for 1 min. Expression of the target genes was calculated using the formula 2 -ΔΔCt . Expression data were normalized to the expression of the β-actin gene.
Western blot analysis. Western blot analysis was used to confirm gene silencing as described previously (21) . Briefly, cell extracts containing 30 µg total protein were subjected to SDS-PAGE and then transferred onto PVDF membranes. The membranes were blocked and probed with primary antibodies that recognized ERRα (ab41868; Abcam) or β-actin (sc-47778; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Secondary antibodies were chosen according to the species of origin of the primary antibodies. After the incubation, the luminescent signals were detected using an enhanced chemiluminescence kit (Pierce, Rockford, IL, USA).
Statistical analyses.
All experiments were performed at least three times. Each value is expressed as the mean ± SD. Comparisons between two groups were performed by the independent samples t-test. Differences among three or more groups were analyzed by one-way ANOVA, followed by Dunnett's test for significance. Data with a P-value of <0.05 was considered to represent a statistically significant difference.
Results

Characterization of hPDLSCs.
Stem-like cells were successfully isolated from the human PDL tissue. To characterize the phenotypic stem cell markers of single colony-derived PDLSCs, the expression levels of STRO-1, CD29, CD34, CD45 and CD105 were analyzed by flow cytometry. We observed that the hPDLSC population showed a high percentage of cells expressing markers of MSCs: STRO-1, CD29 and CD105 (Fig. 1A) . In contrast, the cells were negative for the hematopoietic lineage marker CD34 and the leukocyte common antigen CD45 (Fig. 1A) . To evaluate the multipotency of PDLSCs, we performed Oil Red O staining after culturing in adipogenic induction medium for 14 days and Alizarin Red S staining after culturing in osteogenic induction medium for 21 days. The results showed that hPDLSCs had strong adipogenic and osteogenic differentiation capacities (Fig. 1B and C) .
Expression of ERRα in hPDLSCs.
Immunocytochemistry and RT-PCR analyses were employed to examine the expression of ERRα in cultured hPDLSCs. As shown in Fig. 2A , a clear band representing ERRα was detected in the hPDLSCs at the same molecular weight as that in positive control cells (MCF-7 cells). Immunocytochemical staining confirmed the positive expression of ERRα protein in the hPDLSCs (Fig. 2B) and MCF-7 cells (Fig. 2C) . Positive signals in the nuclei were stronger than those in the cytoplasm of the hPDLSCs (Fig. 2B) . In contrast, no positive signal was found in the negative control (Fig. 2D) .
Temporal expression of ERRα in hPDLSCs treated with osteogenic induction medium. To investigate the role of ERRα in osteogenic differentiation of hPDLSCs, we measured the expression of ERRα mRNA during osteogenic induction (day 1, 7, 14 and 21) of hPDLSCs by quantitative real-time PCR (Fig. 3 ). There were no significant differences between the osteogenic induction group and the control group at day 1 and 7. As the cells entered the mineralization stage after culturing for 14 days, ERRα mRNA expression in the osteogenic induction group was significantly increased (P<0.05), and at day 21, it reached a peak level compared with that in the control group (P<0.001).
Knockdown of the expression of ERRα results in decreased osteogenic differentiation of hPDLSCs.
To further analyze the biological function of ERRα, we used lentiviral vectors driving the expression of miRNA against the ERRα gene. DNA sequencing results revealed that the inserted fragments were correct, and no mutations were found in the recombinant plasmids. Successful transfection of recombinant plasmids into hPDLSCs was confirmed by detecting EmGFP expression under a fluorescence microscope (Fig. 4A-D) . After stably transfected cell lines were produced by culturing in selection medium containing blasticidin for 2 weeks, flow cytometric analysis showed that the transfection rate of LV-miR-neg and LV-miR-ERRα was >90%. Fig. 4F-H shows the EmGFP expression in hPDLSCs stably transfected with LV-miR-neg or LV-miR-ERRα. Gene silencing was confirmed by real-time PCR after culturing in osteogenic induction medium for 7, 14 and 21 days, and by western blot analysis at day 7 ( Fig. 4I and J) . The results showed that transfection with LV-miR-ERRα decreased ERRα mRNA and protein expression by ~50%.
Next, we determined the osteogenic capacity of hPDLSCs transfected with LV-miR-ERRα, and used the cells transfected with LV-miR-neg as the control. ALP and Alizarin Red S staining were performed to detect the mineralization of hPDLSCs (Fig. 5A) . The density of ALP staining at day 14 was lower in the ERRα-knockdown group than that in the control group (P<0.01) and Alizarin Red S staining at day 21 also showed a significant decrease in the mineralization of hPDLSCs transfected with LV-miR-ERRα (P<0.01).
We next monitored the mRNA expression of some mineralization-related genes in hPDLSCs cultured in osteogenic induction medium at day 7, 14 and 21. We observed significant decreases in ALP, RUNX2, OCN and OPN mRNA levels in ERRα-knockdown cells (P<0.05) (Fig. 5B) . Taken together, our data indicate that ERRα promotes osteogenic differentiation of hPDLSCs. 
Discussion
ERRα is capable of regulating the transcription of genes involved in multiple cellular and physiological processes (3, 8, 22) . Studies have established the key roles of ERRα in regulating mitochondrial biogenesis (3), fatty acid oxidation (23) and oxidative phosphorylation (3) and have correlated ERRα with various types of cancer and metabolic disorders (22) . ERRα has also been proposed as an important regulatory factor of bone metabolism (8) and is regarded as a potential therapeutic target for treating osteoporosis (24) .
Previous studies have shown that ERRα is selectively expressed in a variety of cell types during development and in adult tissues, and ERRα expression increases according to metabolic demands (8, 23) . ERRα is highly expressed during the formation of ossification zones during mouse development in vivo (25) , as well as in primary rat calvarial cells in vitro (9) . Nevertheless, its expression in periodontal tissues has not been studied. PDLSCs are isolated from the PDL that connects two types of hard tissues, tooth cementum and alveolar bone, and thus express an array of cementoblastic/osteoblastic markers. PDLSCs are capable of forming cementum/PDL-like tissue, and participate in the repair of alveolar bone (16) . In addition, healthy cells can be easily obtained from adolescents who require teeth extraction for orthodontic reasons. Therefore, PDLSCs are ideal seed cells for periodontal tissue engineering therapies. Since PDL is also a highly metabolically active tissue with peculiar mechanical/functional demands (26), we investigated ERRα expression in PDLSCs in vitro.
Osteogenic differentiation of hPDLSCs is a complex process regulated by multiple signals at different levels. Since ERRα was expressed in hPDLSCs, we assumed that ERRα was also involved in osteogenic differentiation of hPDLSCs. We monitored the expression of ERRα as the cells were induced to differentiate in osteogenic induction medium, and found a gradual increase in the expression levels of ERRα. We next used RNA interference to inhibit ERRα expression in hPDLSCs. Downregulation of ERRα significantly inhibited the mineralization capacity of hPDLSCs. We further detected the expression of mineralization-related genes during the osteogenic differentiation of hPDLSCs. ALP and OCN are regarded as indicators of early and late osteogenesis, respectively. RUNX2 is a key transcription factor essential for the commitment of multipotent mesenchymal cells to the osteoblast lineage, and serves as an early transcriptional regulator of osteogenic differentiation (27) . OPN is a noncollagenous bone matrix protein, a marker of the late stages of osteoblastic differentiation, and its promoter can be transactivated by ERRα (28). These mineralization-related genes were downregulated by lentiviral-mediated ERRα knockdown, suggesting that ERRα initiates early-stage osteogenic differentiation and maintains late-stage osteogenic differentiation of hPDLSCs in vitro.
In a recent study, Rajalin et al (12) also proposed a positive role for ERRα in osteoblastic differentiation of MSCs using ERRα-knockout (KO) mice. Auld et al (13) showed similar results regarding the role of ERRα in mineralization of human MSCs and they found that native ERRα represses Wnt signaling, which has been shown to suppress osteogenesis in the human MSC system (29) . Our results also showed that lentiviral-mediated ERRα knockdown reduced the osteogenic differentiation of PDLSCs that are tissue-specific MSCs. However, the mechanism by which ERRα enhances the osteogenic potential of MSCs is still unclear. Previous studies have shown that overexpression of ERRα leads to induction of the p21 cell cycle inhibitor, and inhibition of proliferation in breast cell lines (30, 31) . Based on these studies, we inferred that, upon silencing in MSCs, ERRα may enhance cell expan- sion and lead to delayed differentiation. However, a report by Delhon et al (14) showed a negative effect of ERRα on bone formation both in vivo and in vitro. Teyssier et al (15) also found that ERRα negatively regulates osteogenic differentiation in vitro and demonstrated a gender-dependent effect of ERRα in ERRα-KO mice. These contradictions may result from differences in the tissues and species, variability of the primary cell cultures, differences in the osteogenic culture conditions, the genetic backgrounds of the ERRα-KO mice, or potential gender-dependent effects of ERRα (12) .
ERRα has crosstalk with ERs and estrogen and modulates ER-mediated signaling pathways (8) . Studies have shown that ERRα is a potential therapeutic target of postmenopausal osteoporosis (24) . Since postmenopausal osteoporosis is a well-known systemic inflammatory environment, and periodontitis is also a chronic inflammatory microenvironment, we theorized that ERRα may be involved in periodontal disease (32) . Previous studies by our group demonstrated that hPDLSCs derived from patients with chronic periodontitis (P-PDLSCs) display an impaired osteogenic potential compared with that of hPDLSCs derived from healthy donors (H-PDLSCs) (33) . We also observed that ERRα expression is decreased in P-PDLSCs, and when H-PDLSCs are treated with TNF-α, the main proinflammatory factor of periodontitis, the expression of ERRα is significantly decreased along with the attenuation of osteogenic differentiation (unpublished data). Similarly, Bonnelye et al (34) found that ERRα mRNA expression is downregulated in the subchondral bone of mice with induced joint inflammation, which is paralleled by downregulation of markers of bone formation. Therefore, ERRα may be involved in impaired osteogenic differentiation of hPDLSCs in periodontal disease, and we believe that ERRα may also be a promising therapeutic target for treating inflammatory bone diseases such as local periodontitis and systemic osteoporosis. However, the pathway through which inflammatory diseases affect ERRα expression and the relationship between ERRα, ERs and estrogen are far from clear and need further investigation.
In conclusion, we detected the expression of ERRα in hPDLSCs in vitro and observed positive effects of ERRα on the osteogenic differentiation of hPDLSCs. This result suggests that ERRα regulates osteogenic differentiation of PDLs and may be involved in the pathogenesis of estrogenrelated periodontal disease. Further studies are required to investigate the specific functions of ERRα in periodontal tissues including periodontal ligaments, gingiva and alveolar bone under different physiological and pathophysiological conditions, and the crosstalk between ERRs and ERs to elucidate the mechanisms through which ERRα acts both in bone loss due to estrogen deficiency and in periodontal issues.
